pCR Rates in Patients With Bilateral Breast Cancer After Neoadjuvant Anthracycline-Taxane Based-Chemotherapy. A Retrospective Pooled Analysis of Individual Patient Data From Four German Neoadjuvant Trials

Researchers from Germany noted that patients with bilateral breast cancer (BBC) are usually excluded from participating in clinical trials and, thus, little is known about the response rates and outcomes associated with neoadjuvant chemotherapy compared with patients with unilateral BC (UBC). They concluded that patients with BBC had lower pCR rates and a lower DFS than patients with UBC.